(±)-MDMA and its enantiomers: potential therapeutic advantages of R(−)-MDMA

@article{Pitts2017MDMAAI,
  title={(±)-MDMA and its enantiomers: potential therapeutic advantages of R(−)-MDMA},
  author={E. Pitts and D. Curry and Karly Hampshire and M. B. Young and L. Howell},
  journal={Psychopharmacology},
  year={2017},
  volume={235},
  pages={377-392}
}
The use of (±)-3,4-methylenedioxymethamphetamine ((±)-MDMA) as an adjunct to psychotherapy in the treatment of psychiatric and behavioral disorders dates back over 50 years. Only in recent years have controlled and peer-reviewed preclinical and clinical studies lent support to (±)-MDMA’s hypothesized clinical utility. However, the clinical utility of (±)-MDMA is potentially mitigated by a range of demonstrated adverse effects. One potential solution could lie in the individual S(+) and R… Expand
12 Citations
Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions
  • 15
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.
  • 15
Better living through chemistry: MDMA’s prosocial mechanism as a starting point for improved therapeutics
DARK Classics in Chemical Neuroscience: Aminorex Analogues.
  • 6
Aminorex analogs
  • PDF
The renaissance in psychedelic research: What do preclinical models have to offer.
  • K. Murnane
  • Psychology, Medicine
  • Progress in brain research
  • 2018
  • 12
...
1
2
...

References

SHOWING 1-10 OF 170 REFERENCES
In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys.
  • W. Fantegrossi
  • Chemistry, Medicine
  • Experimental and clinical psychopharmacology
  • 2008
  • 29
Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.
  • 216
Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans
  • 333
  • Highly Influential
  • PDF
The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder
  • 17
  • PDF
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time
  • 55
  • Highly Influential
  • PDF
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
  • 1,100
  • PDF
Safety pharmacology of acute MDMA administration in healthy subjects
  • 53
  • PDF
The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis
  • 46
  • PDF
...
1
2
3
4
5
...